Norway Savings Bank increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 696.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 757 shares of the medical research company’s stock after acquiring an additional 662 shares during the period. Norway Savings Bank’s holdings in Thermo Fisher Scientific were worth $352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in TMO. Eastern Bank raised its holdings in Thermo Fisher Scientific by 16.3% during the second quarter. Eastern Bank now owns 7,545 shares of the medical research company’s stock valued at $2,734,000 after buying an additional 1,056 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Thermo Fisher Scientific by 3.8% during the second quarter. Principal Financial Group Inc. now owns 829,798 shares of the medical research company’s stock valued at $300,668,000 after buying an additional 30,433 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Thermo Fisher Scientific by 2.2% in the second quarter. PNC Financial Services Group Inc. now owns 262,741 shares of the medical research company’s stock valued at $95,202,000 after purchasing an additional 5,543 shares during the last quarter. FMR LLC grew its position in shares of Thermo Fisher Scientific by 3.3% in the second quarter. FMR LLC now owns 11,621,011 shares of the medical research company’s stock valued at $4,210,756,000 after purchasing an additional 376,531 shares during the last quarter. Finally, Level Four Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 3.8% in the second quarter. Level Four Advisory Services LLC now owns 1,207 shares of the medical research company’s stock valued at $434,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 88.12% of the company’s stock.

NYSE TMO traded up $2.94 during trading on Wednesday, reaching $501.71. 1,329,454 shares of the company traded hands, compared to its average volume of 1,981,069. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.02 and a current ratio of 2.62. The stock’s 50 day moving average price is $470.61 and its two-hundred day moving average price is $441.63. The company has a market cap of $198.85 billion, a price-to-earnings ratio of 53.98, a P/E/G ratio of 1.86 and a beta of 0.98. Thermo Fisher Scientific Inc. has a 1-year low of $250.21 and a 1-year high of $532.57.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 21st. The medical research company reported $5.63 earnings per share for the quarter, beating analysts’ consensus estimates of $4.37 by $1.26. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The company had revenue of $8.25 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the business earned $2.94 earnings per share. The company’s quarterly revenue was up 31.6% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 15.99 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Thursday, November 5th that authorizes the company to repurchase $2.50 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.18%. The ex-dividend date is Monday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.13%.

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $479.94, for a total value of $4,799,400.00. Following the completion of the transaction, the chief executive officer now owns 228,694 shares in the company, valued at $109,759,398.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Mark Stevenson sold 14,133 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 7th. The shares were sold at an average price of $473.84, for a total transaction of $6,696,780.72. Following the completion of the transaction, the chief operating officer now owns 58,005 shares of the company’s stock, valued at approximately $27,485,089.20. The disclosure for this sale can be found here. Insiders sold 38,246 shares of company stock valued at $18,220,461 in the last quarter. 0.44% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently issued reports on TMO shares. Needham & Company LLC raised their price target on Thermo Fisher Scientific from $477.00 to $539.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and lowered their price target for the company from $550.00 to $500.00 in a research report on Wednesday, December 16th. SVB Leerink raised their price target on Thermo Fisher Scientific from $470.00 to $525.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Morgan Stanley raised their price target on Thermo Fisher Scientific from $485.00 to $535.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, Robert W. Baird raised their price target on Thermo Fisher Scientific from $512.00 to $523.00 and gave the company an “outperform” rating in a research report on Wednesday, December 2nd. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $492.58.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Recommended Story: Trading Ex-Dividend

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.